The Cancer Genome Atlas (TCGA) Clinical Data Reporting Form - GBM		Barcode Internal Use Only	
			1. Completed By:
Tissue Source Site (TSS) Name:			Date: film D D Y Y
Tier 1 Clinical Data Definition: All of these elements (1-22) are required to "qualify" the tumor specimen for TCGA project.		2. Completed By: Date: 61 M D D Y Y	
Tier 1 (Clinical Data (Page 1 of 3)		
Tier#	Data Element Label	Entry Alternatives	caBIG Definition
1: 01	TSS Unique Patient #		
1: 02	Organ of Origin – GBM	Brain Lung Ovary	Text term for originating or primary anatomic site of the disease/condition under investigation or review. (2735776)
1: 03	Histological Type: a. Untreated primary (De Nova) GBM b. Prior brain tissue diagnosis of lower grade Glioma	Yes No Yes No	Text term to indicate whether or not a brain tumor is the first occurrence of Glioblastoma Multiforme, which forms from glial (supportive) tissue of the brain and grows quickly. (2753300) Text term to signify if a person had an earlier diagnosis of glioma with a lower histologic grade than the current glioma grade. (2786111)
1:04	Gender	Male Female	Text designations that identify gender. Gender is described as the assemblage of properties that distinguish people on the basis on their social roles. [Explanatory Comment 1: Identification of gender is based upon self-report and may come from a form, questionnaire, interview, etc. (2200604)
1: 05	Date of Birth	M M D D Y Y	Person's Birth date (2201154)
1: 06	Reserved for Future Use		
1: 07	Tobacco smoking history indicator (Ovary-GBM: N/A)	N/A	Text indicator to represent a person's tobacco smoking, the act of puffing and/or inhaling smoke from a lit tobacco cigarette, cigar, or pipe. (2436233)
1: 08	Date of initial pathologic diagnosis	MIMI D D Y Y	The date this disease was first diagnosed. (58204)
1: 09	Neo-adjuvant (pre-operative) therapy (If yes, this is an exclusion criterion)	Yes No	The yes/no indicator to ask whether any treatment was given to the patient prior to surgery. (64176)
1: 10	Date of Surgical Resection	MI MI D D Y Y	The date of a surgical procedure. (2003986)

TCGA Clinical Data Reporting Form - GBM			Barcode
	TSS Name:TSS Identifier #:		Internal Use Only
	TSS Unique Patient #		
Tier 1 C	Clinical Data (Page 2 of 3)		
Tier#	Data Element Label	Entry Alternatives	caBIG Definition
1: 11	Tumor Stage (pathological) GBM	N/A	Text term to represent the name of the histologic category or classification of a brain tumor. (2467507)
1: 12	Tumor Grade: GBM	N/A	Numeric value to express the degree of abnormality of cancer cells, a measure of differentiation and aggressiveness. (2785839)
1: 13	Complete Excision (RO)	Yes (RO) No (R1) Unknown	Term to signify the complete removal or excision by surgical means of the primary tumor, so that surgical margins are free of gross and microscopic tumor. (2785845)
1: 14	Adjuvant (Post-Operative) Irradiation therapy	Yes No Unknown	Yes/no indicator to ask if therapeutic application if radiation was initiated to treat disease following surgery to remove tumor and associated malignant tissue. (2005312)
1: 15	Adjuvant (Post-Operative) Chemotherapy	Yes No Unknown	Text term to indicate whether a patient has received adjuvant postoperative chemotherapy. (2756823)
1: 16	Adjuvant (Post-Operative) Immunotherapy	Yes No Unknown	Text term to indicate whether a patient has received adjuvant postoperative Immunotherapy. (2756814)
1: 17	Adjuvant (Post-Operative) Hormonal Therapy	Yes No Unknown	Yes/no/unknown indicator whether adjuvant hormone therapy was administered following surgery. (2199669)
1: 18	Adjuvant (Post-Operative) "Targeted" Molecular Therapy	Yes No Unknown	Text term to signify postoperative adjuvant cancer therapies which use drugs to act upon specific molecules, metabolic pathways or processes involved in carcinogenesis, tumor growth, or tumor spread. (2785850)
1: 19	Date of first Recurrence after therapy	N/A Unknown	N/A =Tumor has not recurred at time of last clinical evaluation. (See 1:20) The date related to the diagnosis or recognition of the presence and nature of the return of signs and symptoms of cancer after a period of improvement.(2663381)
1: 20	Date of Last Contact (clinical evaluation)	61 f.1 D D Y Y	The date of the last successful contact with the patient, family member, or caregiver to establish responses for 1:21 and 1:22 below. (2004147)

	rcua cillicai Data Reporting		Darcoue
	TSS Name:	TSS Identifier #:	Internal Use Only
0001 0001 0001 0001 0001 0001 0001 0001	TSS Unique Patient #		
Tier 1 (Clinical Data (Page 3 of 3)		
1: 21	Vital Status (date of last contact)	Living Deceased Unknown	Test summary level description of patient / participant survival status. (2190384)
1: 22	Date of Death	N/A N/A NI M D D Y Y	The actual date of a patients/participants death (2004152)
Comme	ents:		
		Print Name	
Principal Investigator Signature		Print Name	ואו טט ז ז

The Cancer Genome Atlas (TCGA) Clinical Data Reporting Form – GBM				Barcode Internal Use Only
Tions Course Site (TSS) No year			1. Completed	Ву:
Tissue Source Site (TSS) Name:			Date:	M.M. D. D. Y. Y
TSS Uni	que Patient #		2. Completed	Ву:
Tier 2 Clinical Data Definition: Desirable, but not manditory clinical information for clinical correlation analyses.		•	Date:	A1 M D D Y Y
Tier 2	Clinical Data (Page 1 of 4)			T
Tier # 2: 02	Data Element Label Anatomic Organ Sub- Division a. Brain b. Lung c. Ovary	Entry Alternatives Brain N/A Lung R Upper Middle Lower L Upper Lower Ovary Right Left Bilateral		caBIG Definition Anatomic organ: Text term for originating of primary anatomic site of the disease/condition under investigation or review. (2735776) Detailed spatial description to provide the exact location of an anatomic site or location. (2008006)
2: 08	Method of initial pathologic diagnosis (check all that apply)	Unknown Cytology (e.g. peritoneal or fluid) Fine needle aspiration biops Incision biopsy Excisional biopsy Tumor resection Other method, specify: Unknown		Method: Text name of the procedure to secure the tissue used for the original pathologic diagnosis. (2757941) Other method: Text to describe a method used to secure tissue for an original pathologic diagnosis that is different from other identified methods. (2757948)
2: 14	Adjuvant (Post-operative) Irradiation therapy	No Yes (If yes, complete Disease Tre Regimen Supplemental forn Radiation)		Yes/no indicator to ask if therapeutic application of radiation was initiated to treat disease following surgery to remove tumor and associated malignant tissue. (2005312)
2:15	Adjuvant (Post-operative) Chemotherapy	No Yes (If yes, complete Disease Tre Regimen Supplemental forn Pharmaceutical Therapy)		Text term to indicate whether a patient has received adjuvant postoperative chemotherapy. (2756823)
2: 16	Adjuvant (Post-operative) Immunotherapy	☐ No☐ Yes (If yes, complete Disease Tre Regimen Supplemental forn Pharmaceutical Therapy)		Text term to indicate whether a patient has received adjuvant postoperative Immunotherapy. (2756814)

	TCGA Clinical Data Reporting F	form - GBM	Barcode
	TSS Name:	TSS Identifier #: Internal Use Only	
	TSS Unique Patient #		
Tier 2 (Clinical Data (Page 2 of 4)		
Tier#	Data Element Label	Entry Alternatives	caBIG Definition
2: 17	Adjuvant (Post-operative) Hormone therapy	☐ No ☐ Yes (If yes, complete Disease Treatment Regimen Supplemental form for: Pharmaceutical Therapy)	Yes/no/unknown indicator whether adjuvant hormone therapy was administered following surgery. (2199669
2: 18	Adjuvant (Post-operative) Targeted Molecular Therapy	☐ No ☐ Yes (If yes, complete Disease Treatment Regimen Supplemental form for: Pharmaceutical Therapy)	Text term to signify postoperative adjuvant cancer therapies which use drugs to act upon specific molecules, metabolic pathways or processes involved in carcinogenesis, tumor growth, or tumor spread. (2785850)
2: 00A	Race	□ American Indian or Alaska Native (A person having origins in any of the original peoples of North and South America (including Central America), and who maintains tribal affiliation or community attachment) □ Asian (A person having origins in any of the original peoples of the Far East, Southeast Asia, or the Indian subcontinent including, for example, Cambodia, China, India, Japan, Korea, Malaysia, Pakistan, the Philippine Islands, Thailand, and Vietnam) □ White (A person having origins in any of the original peoples of Europe, the Middle East, or North Africa) □ Black or African American (A person having origins in any of the black racial groups of Africa. Terms such as "Haitian" or "Negro" can be used in addition to "Black or African American.") □ Native Hawaiian or other Pacific Islander (A person having origins in any of the original peoples of Hawaii, Guam, Samoa, or other Pacific Islands) □ Not Reported (Not provided or available) □ Unknown (Could not be determined or unsure)	The text for reporting information about race based on the Office of Management and Budget (OMB) categories. (2192199)
	Ethnicity	□ Not Hispanic or Latino (A person not meeting the definition for Hispanic or Latino) □ Hispanic or Latino (A person of Mexican, Puerto Rican, Cuban, Central or South American or other Spanish culture or origin, regardless of race) □ Not reported (Not provided or available) □ Unknown (Could not be determined or unsure)	The text for reporting information about ethnicity based on the Office of Management and Budget (OMB) categories. (2192217)

	TCGA Clinical Data Reporting Form - GBM		Barcode		
	TSS Name:TSS Identifier #:		Internal Use Only		
200 100 100 100 100 100 100 100 100 100	TSS Unique Patient #		·		
Tier 2	Tier 2 Clinical Data (Page 3 of 4)				
Tier#	Data Element Label	Entry Alternatives	caBIG Definition		
2: 21	Vital Status	Living (cancer status)	The state or condition of an		
	A. Living	Tumor Free	individual's neoplasm at a particular		
	7 2.71118	☐ With Tumor	point in time. (2759550)		
	B. Deceased	Unknown Tu	imor Status		
	D. Deceased	Deceased (cancer status)	inioi statas		
		Tumor Free	The state or condition of an individual's		
		☐ With Tumor	neoplasm at a particular point in time.		
		Unknown Tu	(2759550)		
2: 00B	Performance Status Scale	□ Not Recorded	inioi statas		
2.006	Performance Status Scale		Score from the Karnofsky Performance		
		Karnofsky Score ☐ 100 asymptomatic	status scale, representing the		
	(complete Karnefely, Score	☐ 100 asymptomatic☐ 80-90 symptomatic but fully	functional capabilities of a person.		
	(complete Karnofsky Score Or	60-70 symptomatic but in be	[(2003033)		
	_	50% of day			
	Eastern Cancer Oncology Group)	\square 40-50 symptomatic, in bed r			
	αιουρ)	50% of the day, but n	ot bed		
		ridden	The ECOG functional performance		
		☐ 20-30 bed ridden	and the second second		
		Eastern Cancer Oncology Gr	(88)		
		(ECOG)	(33)		
		0 asymptomatic			
		1 symptomatic but fully an			
		2 symptomatic but in bed I	ess then		
		50% of day	th 500/		
		3 symptomatic, in bed mor of the day, but not bed			
		4 bed ridden	iniden		
		— 4 bed fiddefi			
		Timing of score:			
		☐ Preoperative			
		☐ Pre-adjuvant therapy			
		Post-adjuvant therapy			
		Other			
2: 00C	Cocondon, Compon, for town	☐ Unknown ☐ None	Indicator: The yes/no/unknown		
2: 00C	Secondary Surgery for tumor	☐ None	indicator that asks whether the		
	recurrence or progression	Loco-regional procedure:	recurrence was treated by surgery.		
		☐ Unknown	(2199761)		
		No	Procedure: Name of the secondary		
			surgical procedure performed for		
			recurrent or progressive disease.		
			(2759612)		
		Maladada a a a a	Date: Date of the secondary surgical		
		Metastasis procedure:	procedure performed for recurrent or		
		☐ Unknown ☐ No	progressive disease. (2759616)		
		Yes			
		MM DD Y	Y		

Draft V2.9 01 Oct 2008 6

	TCGA Clinical Data Reporting F	Form - GBM	Barcode		
	TSS Name:	_ TSS Identifier #:	Internal Use Only		
2004 0004 0004 0004 0004 0004 0004 0004	TSS Unique Patient #				
Tier 2 (Clinical Data (Page 4 of 4)				
Tier#	Data Element Label	Entry Alternatives	caBIG Definition		
2: 00D	Additional treatment of tumor recurrence/progression Irradiation therapy	☐ No ☐ Yes (If yes, complete Disease Tr Regimen Supplemental form Radiation)			
2: 00E	Additional treatment of tumor recurrence/progression Chemotherapy	No Yes (If yes, complete Disease Tr Regimen Supplemental form Pharmaceutical Therapy)	· · · · · · · · · · · · · · · · · · ·		
2: 00F	Additional treatment of tumor recurrence/progression Immunotherapy	No Yes (If yes, complete Disease Tr Regimen Supplemental forr Pharmaceutical Therapy)			
2: 00G	Additional treatment of tumor recurrence/progression Hormone Therapy	☐ No ☐ Yes (If yes, complete Disease Tr Regimen Supplemental form Pharmaceutical Therapy)	,		
2: 00H	Additional treatment of tumor recurrence/progression Targeted molecular therapy	☐ No ☐ Yes (If yes, complete Disease Tr Regimen Supplemental forr Pharmaceutical Therapy)			
Comments:					
Principa	al Investigator Signature	Print Name	MM DD YY		

Draft V2.9 01 Oct 2008 7